BIG
KYMR icon

Brooklyn Investment Group’s Kymera Therapeutics KYMR Stock Holding History

Brooklyn Investment Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,344
Closed -$190K – 1773
2025
Q2 		$190K Buy
4,344
+4,338
+72,300% +$149K 0.02% 643
2025
Q1 		$165 Sell
6
-137
-96% -$4.99K ﹤0.01% 2656
2024
Q4 		$5.75K Buy
+143
New +$6.46K ﹤0.01% 1162

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Brooklyn Investment Group's KYMR Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 4,344 shares — an estimated $190K sold.

Brooklyn Investment Group first reported a position in KYMR in Q4 2024 and held it in 3 quarters. The position peaked at $190K in Q2 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 4,344 Kymera Therapeutics shares in Q3 2025, an estimated $190K.
  • Brooklyn Investment Group first reported a position in Kymera Therapeutics in Q4 2024 and held it in 3 quarters.
  • Brooklyn Investment Group's Kymera Therapeutics position peaked at $190K in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.